The Interaction of Antiviral Drugs with SARS-Cov-2 3CL Protease

Abstract

SARS COV2 is one of the most destructive pandemics the world has faced and led to extreme economic losses. For its clinical therapy,
SARS-COV-2 3CL Protease (3CLpro) is considered a target because of its crucial role in replication. Inhibition of this 3CLpro can lead to
a decrease in viral load and infection. Different studies used various compounds and tested their inhibiting activity. Among them, flavonoids,
serine derivatives, Chalcones, and alpha-keto amides were proven to have inhibitory effects. Many in-vitro tests were done to check the
binding and inhibition abilities of such compounds. In vivo, some studies are done, but more is needed to prove this discovery. As far as
research is concerned, therapeutic drugs against COVID-19 can be made by using such inhibitors. More in vivo studies and animal model
experimentation should be done to confirm the findings.